Back to top
more

Cybin Inc. (CYBN)

(Delayed Data from AMEX)

$9.99 USD

9.99
45,784

-0.04 (-0.40%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $9.93 -0.06 (-0.60%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

What Makes Cybin Inc. (CYBN) a New Buy Stock

Cybin Inc. (CYBN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Down -17.45% in 4 Weeks, Here's Why Cybin Inc. (CYBN) Looks Ripe for a Turnaround

Cybin Inc. (CYBN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Kanishka Das headshot

Cybin (CYBN) Begins Phase II Study on Anxiety Drug, Stock Up

Cybin (CYBN) initiates a phase II proof-of-concept study evaluating CYB004 for the treatment of generalized anxiety disorder. The stock rises 7.2%.

Is Cybin Inc. (CYBN) Stock Outpacing Its Medical Peers This Year?

Here is how Cybin Inc. (CYBN) and Alpine Immune Sciences, Inc. (ALPN) have performed compared to their sector so far this year.

Brian Bolan headshot

Brian's Big Idea on Biotech

A look at drugs for drug addiction and the biotech space.

Is Amedisys (AMED) Stock Outpacing Its Medical Peers This Year?

Here is how Amedisys (AMED) and Cybin Inc. (CYBN) have performed compared to their sector so far this year.

Is Cybin Inc. (CYBN) Stock Outpacing Its Medical Peers This Year?

Here is how Cybin Inc. (CYBN) and IPSEN (IPSEY) have performed compared to their sector so far this year.

Andrew Rocco headshot

3 Biotech Stocks Aiming to Reinvent Mental Health Treatment

Atai, Biogen, and Sage are working to develop new treatments for mental illness.

Brian Bolan headshot

Bull Of The Day: Cybin (CYBN)

Instead of a hangover, the side effect from this treatment has been described as an "after glow."

Cybin (CYBN) Up on FDA Clearance of IND for CYB003 in MDD

Cybin (CYBN) receives a "may proceed letter" and IND application clearance from the FDA for a phase I/IIa study evaluating CYB003 for potential treatment of major depressive disorder. Shares up.